Axona is a medical food that is metabolized into ketone bodies, which the brain can use for energy even when its ability to process glucose is impaired. Brain-imaging scans of older adults and those with Alzheimer’s disease reveal a dramatically decreased uptake of glucose, the brain’s preferred source of energy. Axona is being developed to replace these depleted glucose levels to treat age-associated memory impairment (AAMI) and Alzheimer’s disease.
Axona is specifically indicated for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer’s disease.
Axona is supplied as a powder for oral formulation. Axona should be administered once daily at breakfast.
Submit your review
Adverse events associated with the use of Axona may include, but are not limited to, the following:
The recommended dosage is 40 grams (one packet of Axona powder, containing 20 grams MCTs) per day. The contents of each packet of Axona should be added to 4 to 8 ounces (118 to 236 milliliters) of water, as preferred, shaken until fully blended, and consumed immediately.